TGFB1 and Myocardial fibrosis: The inhibition of miR-34a in vivo can reduce the severity of myocardial fibrosis in experimental mice, while miR-34a overexpression can increase the fibrogenic activity of TGF-β1 in cardiac fibroblasts.